



Combat Drugs Limited

Corp. Off: 201, 3rd Floor, Moghul Emami Mansion, Khairatabad, Hyderabad – 500004, TS
Regd. Off: 1-1-490, Plot No.63, Road No.4, Mohan Nagar, R. R. District -500035, Telangana
Ph: +91-40-66200100 / 23374169 Url: www.combatdrugs.in Email: info@combatdrugs.in
CIN No.:L24230TG1986PLC006781 TIN: 36690236431 D.L.No.:41/RR/AP/03/F/R & TG/25/02/2015-5522/5523

13/02/2016

To,
The General Manager
Department of Corporate Services – CRD
BSE Limited
P. J. Towers,
Dalal Street, Mumbai – 400001

Sir,

Ref: Scrip Code 524752
Sub: Outcome of Board Meeting

This is to inform you that the meeting of the Board of Directors of the company was held today ie; 13th February, 2016. The Board Considered and approved the following:


1. The Un-Audited Financial Results for the Quarter and nine months ended 31st December, 2015.
2. The Limited Review Report of the Statutory Auditor for the period ended 31st December, 2015.
3. Adopted the New Listing Agreement pursuant to the Provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to be entered with BSE Limited.

This is for your information and records.

Thanking You
Yours Sincerely,

For **COMBAT DRUGS LIMITED**

COMPLIANCE OFFICER



COMBAT DRUGS LIMITED

(CIN NO. CL23230TG1986PLC006781)

Regd. Off : 1-1-490, Plot No. 63, Road.
No. 4, Mohan Nagar, R.R. District -
500 035, TELANGANAPh: 040-66200100
URL: www.combatdrugs.in
Mail: info@combatdrugs.in**UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2015****Amount - Rs in.Lacs**

	Particulars	3 months ended			9 months ended		Previous accounting year ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Net Sales/Income from Operations	9.91	4.47	5.70	16.84	8.55	9.63
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total income from operations	9.91	4.47	5.70	16.84	8.55	9.63
2	2. Expenditure						
	a. Increase/decrease in stock in trade and work in progress	0.00	0.00	0.00	0.00	0.00	0.00
	b. Consumption of raw materials/Obsolete Stocks written off.	2.83	3.53	4.10	8.10	6.84	7.90
	c. Purchase of traded goods	0.00	0.00	0.00	0.00	0.00	0.00
	d. Employees cost	1:53	1.53	0.15	4.59	2.07	2.97
	e. Depreciation	2.85	2.85	5.20	8.56	15.60	23.21
	f. Other expenditure	4.68	7.52	7.67	17.93	14.3	16.35
	Total	11.89	15.43	17.12	39.18	38.81	50.43
3	Profit /loss from Operations before Other Income, Interest and Exceptional Items (1-2)	(1.98)	(10.96)	(11.42)	(22.34)	(30.26)	(40.80)
4	Other Income	0.25	0.15	3.15	0.40	4.19	8.77
5	Profit before Interest and Exceptional Items (3+4)	(1.73)	(10.81)	(8.27)	(21.94)	(26.07)	(32.03)
6	Interest	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit after Interest but before Exceptional Items (5-6)	(1.73)	(10.81)	(8.27)	(21.94)	(26.07)	(32.03)
8	Exceptional items						
	a) Fixed asset written off	0.00	0.00	109.90	0.00	109.90	336.36
	b) Expired stocks	0.00	28.81	0.00	28.81	0.00	0.00
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	(1.73)	(39.62)	(118.17)	(50.75)	(135.97)	(368.39)
10	Tax expense	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax	(1.73)	(39.62)	(118.17)	(50.75)	(135.97)	(368.39)
12	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit(+)/ Loss(-) for the period (11-12)	(1.73)	(39.62)	(118.17)	(50.75)	(135.97)	(368.39)
14	Paid-up equity share capital	800.00	800.00	800.00	800.00	800	800.00
15	Reserve excluding Revaluation Reserves as per balance sheet of previous account year						(460.00)
16	Earnings Per Share (EPS)						
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.00	(0.05)	(0.15)	(0.06)	(0.17)	(0.46)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.00	(0.05)	(0.15)	(0.06)	(0.17)	(0.46)

Notes: 1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved and taken on record by the Board of Directors at their meeting held on 13-02-2016. The Statutory Auditors have carried out a Limited Review of the Un-Audited Financial Results of the company for the quarter ended 31.12.2015.

2. The Company is exclusively engaged in only one broad segment of Pharmaceutical Business.

3. Prior period figures have been regrouped/rearranged wherever necessary.

For and on behalf of the Board of Directors

Place: Hyderabad

Date : 13-02-2016



(Signature)
(Suchit Mohan Lal)

MANAGING DIRECTOR

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To

The Board of Directors of
Combat Drugs Limited

We have reviewed the accompanying statement of unaudited financial results of Combat Drugs Limited for the Quarter and Nine Months ended 31st December, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,
Chartered Accountants
FRN: 0001255



A.V. Sadasiva
A.V. Sadasiva
Partner
Membership No. 018404

Place: Hyderabad
Date: 13th February, 2016